Tag Archives: TSRO

Hot Performing Stocks To Own Right Now

In Johnson & Johnson news, the stock is down 1.3% over the last five trading days, and that makes this the perfect time to buy this dividend aristocrat…

The pullback was caused by two analysts downgrading Johnson & Johnson (NYSE: JNJ) on July 21, but analysts simply don’t know how to value JNJ stock.

BTIG Research downgraded JNJ from “Neutral” to “Sell” because it doesn’t think Johnson & Johnson will be able to successfully execute its medical device acquisition.

Alembic Global Advisors downgraded the company from “Neutral” to “Underperforming” but didn’t release its rationale.

Hot Performing Stocks To Own Right Now: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Todd Campbell]

    Tesaro’s (NASDAQ:TSRO)ovarian cancer drug, niraparib, will begin competing for prescriptions earlier than expected. Niraparib, which will be sold under the brand name Zejula, notched FDA approval on Monday, more than three months ahead of its June 30 decision date. The early approval setsTesaro up for a fierce battle for market share withAstraZeneca (NYSE:AZN)and Clovis Oncology (NASDAQ:CLVS), both of which market drugs that work similarly to Zejula.

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

  • [By Ben Levisohn]

    Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:

Hot Performing Stocks To Own Right Now: JinkoSolar Holding Company Limited(JKS)

Advisors’ Opinion:

  • [By Lisa Levin]

    JinkoSolar Holding Co (NYSE: JKS) dropped 9.88% to $16.87 after the company announced the offering of 3,500,000 American Depositary Shares.

    Fuwei Films (Holdings) Co (NASDAQ: FFHL) dropped 9.66% to $1.30. Fuwei Films’ trailing-twelve-month ROE is -10.85%.

  • [By Elizabeth Balboa]

    First Solar, Inc (NASDAQ: FSLR) was trading down 3.7 percent Monday, while JA Solar Holdings Co., Ltd. (ADR) (NASDAQ: JASO) was down 0.8 percent, SunPower Corporation (NASDAQ: SPWR) 4.4 percent, Canadian Solar Inc. (NASDAQ: CSIQ) 5.2 percent and JinkoSolar Holding Co., Ltd. (NYSE: JKS) 4.4 percent.

  • [By Paul Ausick]

    But the real news is the near vertical trajectory in share prices for the two stocks. This could be another manifestation of the markets hunger for some momentum plays, as we noted earlier this morning the bump to share prices for both JinkoSolar Holding Co. Ltd. (NYSE: JKS) and Shutterstock Inc. (NASDAQ: SSTK), both of which held secondary share sales this morning.

  • [By Lisa Levin]

    In trading on Monday, energy shares fell by 0.59 percent. Meanwhile, top losers in the sector included JinkoSolar Holding Co., Ltd. (NYSE: JKS), down 8 percent, and Teekay Offshore Partners L.P. (NYSE: TOO) down 7 percent.

Hot Performing Stocks To Own Right Now: Xcel Energy Inc.(XEL)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Jefferies announced on Wednesday that it has raised its rating on Xcel Energy Inc (XEL).

    The firm has upgraded XEL from “Hold” to “Buy,” and has raised the company’s price target from $31 to $32.50. This new price target suggests a 15% upside from the stock’s current price of $27.72.

    Analyst Paul B. Fremont commented: “The stock is currently trading at an 8% P/E discount to our 2015E group average multiple.”

    “Despite a difficult political environment in Minnesota the company was able to achieve a reasonable outcome in its NSP-Minnesota rate case,” the analyst added.

    Looking forward, the firm has increased its FY2014 outlook from $1.95 to $2.00 per share.

    Xcel Energy shares were mostly flat during pre-market trading Wednesday. The stock has been mostly flat YTD.

Top 10 Performing Stocks To Buy For 2018

March 16, 2017: Markets opened higher again Thursday but the uptick did not last longer. Within an hour shares had dropped and a brief turn higher was foiled quickly. The worst performing sectors for the day are utilities and healthcare, with financials showing the only decent gain. WTI crude oil for April delivery settled at $48.75 a barrel, down 0.2% on the day. April gold added 2.2% on the day to settle at $1,227.10. Equities were headed for a lower close shortly before the bell as the DJIA traded down 0.11% for the day, the S&P 500 traded down 0.22%, and the Nasdaq Composite traded down 0.02%.

The DJIA stock posting the largest daily percentage loss ahead of the close Thursday was E.I. du Pont de Nemours Inc. (NYSE: DD) which traded down 1.14% at $80.56. The stock’s 52-week range is $61.12 to $81.51. Volume was roughly 40% below the daily average of around 2.6 million shares. The company had no specific news.

Chevron Corp. (NYSE: CVX) traded down 1.00% at $107.79. The stock’s 52-week range is $92.25 to $119.00. Volume was about 10% below the daily average of around 6.3 million shares. The integrated oil & gas company had no specific news.

Top 10 Performing Stocks To Buy For 2018: Tobira Therapeutics, Inc.(TBRA)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Allergan (NYSE: AGN) acquired Akarna Therapeutics global rights to AKN-083 for up-front payment of $50 million. This came just hours after Allergan bought Tobira Therapeutics (NASDAQ: TBRA) for upfront Payment of $28.35 share in cash, up to $49.84 per share in CVRs.

Top 10 Performing Stocks To Buy For 2018: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By George Budwell]

    Unfortunately for Clovis and its shareholders, though, Astra’s Lynparza is currently underpriority review with the FDA as a maintenance therapy in ovarian cancer, andTesaro’s (NASDAQ:TSRO)rival PARP inhibitor Zejula gained an early approval– along with afar broader label than Rubraca — just this week.

  • [By Ben Levisohn]

    Who has PARP? A poly ADP-ribose polymerase inhibitor (PARPi) kills cancer cells by interfering tumor DNA repair pathway with the potential to treat ovarian, breast and prostate cancer. Studies have shown that patients with BRCA mutations (BRCAmut) respond to PARPi. AstraZenecas (AZN) PARPi was approved in 2014 whileClovis Oncology (CLVS) and Tesaro (TSRO) both have positive Phase III data. Clovis licensed its PARPi from Pfizer (PFE) in 2011 and Tesaro licensed its PARPi from Merck (MRK) in 2012, after Sanofis (SNY) PARPi (later demonstrated that it cannot block PARP) failed in Phase III in early 2011.

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

Top 10 Performing Stocks To Buy For 2018: Cardiome Pharma Corporation(CRME)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 30 percent to $2.72 after the company issued U.S. regulatory update for BRINAVESS. The FDA advised Cardiome that the data package proposed is not sufficient to support re-submission of the BRINAVESS NDA.

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 43 percent to $3.01. Cardiome priced 10 million shares at $3 per share.

    Seadrill Partners LLC (NYSE: SDLP) was down, falling around 30 percent to $4.09 as the company announced plans to reduce the quarterly cash distribution to $0.10 per unit from $0.25 per unit.

Top 10 Performing Stocks To Buy For 2018: Blackrock Global(BOE)

Advisors’ Opinion:

  • [By Robert Rapier]

    Whiting Petroleum (WLL) is one of Continental’s biggest competitors in the Bakken. Whiting is the second-largest oil producer in North Dakota, averaging 82,500 barrels of oil equivalent (BOE) of production in 2012, across more than 700,000 acres of leased land.

Top 10 Performing Stocks To Buy For 2018: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

Top 10 Performing Stocks To Buy For 2018: Clarke(t)

Advisors’ Opinion:

  • [By Jim Robertson]

    DirecTV is a direct broadcast satellite service provider and is a subsidiary of AT&T Inc (NYSE: T). Its satellite service, launched on June 17, 1994, transmits digital satellite television and audio to households in the United States, Latin America and the Caribbean withprimary competitorsbeing Dish Network and cable television providers. On July 24, 2015, after receiving approval from the FCC and United States Department of Justice, AT&T acquired DirecTV in a transaction valued at $48.5 billion. DirecTV would be paying$1.5 billion a year for the NFL Sunday Ticket.AT&T’s shares may have broken out of a downtrend:

  • [By Brian Feroldi, Dan Caplinger, Rich Duprey, Jason Hall, and Jordan Wathen]

    In order to point you in the right direction, we asked a team of Fools to highlight a dividend stock that they feel is a great stock for a beginner. Read on to see why they picked AT&T (NYSE:T),Apple (NASDAQ:AAPL),Anheuser-Busch InBev(NYSE:BUD), Mastercard(NYSE:MA), andJPMorgan Chase(NYSE:JPM).

  • [By Paul Ausick]

    AT&T Inc. (NYSE: T) dropped about 1.4% Tuesday to post a new 52-week low of $35.87 after closing Monday at $36.39. The 52-week high is $43.50. Volume was around 5.8 million shares traded, nearly 10 times the daily average of around 600,000. The company had no specific news.

  • [By Douglas A. McIntyre]

    At the other end of the iPhone 8 spectrum, wireless companies like AT&T Inc. (NYSE: T) probably will price the low-end version of the iPhone 8 below $40 a month, with 24-month contracts. This kind of price plan is a usual way for large wireless carriers to get and hold customers for long periods. Even if the carrier pays a lot for the smartphone, it presumably makes that back in monthly fees and on people who renew their subscriptions for a longer period.

  • [By Chris Lange]

    AT&T Inc.’s (NYSE: T) second-quarter results are scheduled for Tuesday. The consensus earnings estimate is $0.74 per share, on $39.82 billion in revenue. The shares were last seen at $36.51. The consensus price target is $40.27, and the 52-week trading range is $35.81 to $43.50.

Top 10 Performing Stocks To Buy For 2018: Snap-On Incorporated(SNA)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Coming up on this episode of Mad Money: Cramer interviews Nick Pinchuk, CEO of Snap-on (SNA) . Plus, don’t miss the Lightning Round. Which stocks is Cramer bullish on?

  • [By John Divine]

    Snap-on Incorporated (SNA) is my choice for the Best Stocks for 2016 competition. At a market cap of $10 billion, I doubt it will double over the next year, as some of the smaller companies in this competition might be able to.

    That said, Snap-on, which manufactures and markets hand tools and diagnostic equipment, is a rock-solid company with an attractive valuation and impressive growth. It goes for 22 times earnings, pays a consistent and modest dividend, and has been around since 1920.

    As cars get more tech-heavy and complicated, newer tools and better diagnostics will be needed — and that’s SNA’s bread ‘n’ butter. 

  • [By WWW.MONEYSHOW.COM]

    Snap-on (SNA)

    Snap-on, which is more than 100 years old, provides hand and power tools for individuals and professionals, including auto-shop tools and auto diagnostic equipment.

Top 10 Performing Stocks To Buy For 2018: PRA Group, Inc.(PRAA)

Advisors’ Opinion:

  • [By Lee Jackson]

    PRA Group Inc. (NASDAQ: PRAA) has been hit hard recently, and shareholders may be glad to know that a director took advantage of the sell-off and stepped in to buy shares. That board member bought 143,000 shares of the financial and business services company at prices that ranged from $34.40 to $34.89. The total for the buy was set at $5 million. The stock closed Friday at $32.90, in a52-week range of $21.93 to $42.70. The consensus price target is $40.60.

Top 10 Performing Stocks To Buy For 2018: Tyson Foods Inc.(TSN)

Advisors’ Opinion:

  • [By Lisa Levin] Companies Reporting Before The Bell
    Tyson Foods, Inc. (NYSE: TSN) is expected to report quarterly earnings at $1.38 per share on revenue of $9.86 billion.
    Aecom (NYSE: ACM) is projected to report quarterly earnings at $0.71 per share on revenue of $4.67 billion.
    JD.Com Inc(ADR) (NASDAQ: JD) is estimated to report quarterly earnings at $0.11 per share on revenue of $12.60 billion.
    58.com Inc (ADR) (NYSE: WUBA) is projected to report quarterly earnings at $0.28 per share on revenue of $383.60 million.
    Kamada Ltd (NASDAQ: KMDA) is expected to report quarterly earnings at $0.02 per share on revenue of $25.00 million.
    Palatin Technologies, Inc. (NYSE: PTN) is projected to report quarterly earnings at $0.06 per share on revenue of $28.00 million.
    TheStreet, Inc. (NASDAQ: TST) is estimated to report a quarterly loss at $0.02 per share on revenue of $15.81 million.
    Atlantica Yield PLC (NASDAQ: ABY) is projected to report quarterly earnings at $0.45 per share on revenue of $290.80 million.
    Asure Software Inc (NASDAQ: ASUR) is estimated to report quarterly earnings at $0.15 per share on revenue of $15.26 million.
    Cyren Ltd (NASDAQ: CYRN) is expected to report quarterly loss at $0.06 per share on revenue of $7.90 million.
    Viewray Inc (NASDAQ: VRAY) is estimated to report quarterly loss at $0.12 per share on revenue of $18.58 million.

     

  • [By Peter Graham]

    A long term performance chart shows shares ofmid cap Sanderson Farms more than doubling in value while large cap Tyson Foods, Inc (NYSE: TSN)has more than tripled in value and mid cap Pilgrim’s Pride Corporation (NASDAQ: PPC) has quadrupled in value:

  • [By Peter Graham]

    A long term performance chart shows shares of small cap Sanderson Farms doubling in value while mid cap Pilgrim’s Pride Corporation (NASDAQ: PPC) and large cap Tyson Foods, Inc (NYSE: TSN) have been even better performers albeit shares are below their peaks and have been somewhat volatile:

Top 10 Performing Stocks To Buy For 2018: Oasis Petroleum Inc.(OAS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Oasis Petroleum Inc. (NYSE: OAS) were down 14 percent to $8.60 after the company reported a 32 million share common stock offering. The company announced Delaware Basin acquisition for $946 million and also raised its Q4 production guidance.

  • [By Jon C. Ogg]

    Oasis Petroleum Inc. (NYSE: OAS) rose a whopping 27.8% to $14.98, and the 33.2 million shares was about 2.5 times normal volume. Oasis Petroleum has a 52-week trading range of $3.40 to $15.02 and a consensus analyst price target of $14.54. The company has a total market cap of $3.5 billion.

  • [By Chris Lange]

    Oasis Petroleum Inc. (NYSE: OAS) shares slid on Tuesday after the company announced that it would be buying into the Delaware Basin. Analysts seemed to applaud this move, despite investors sending shares into the fire. Jefferies raised its price target to $14 from $13, and Morgan Stanley raised its target to $11 from $9. RBC has an Outperform rating and raised its target to $14 from $13, while SunTrust Robinson Humphrey downgraded it to Hold from Buy. Shares were down about 14% at $8.67, in a 52-week range of $6.69 to $16.73.

  • [By Paul Ausick]

    Oasis Petroleum Inc. (NYSE: OAS) is rated a Buy and the price target was lifted to $24. For 2017, the net loss estimate improved from a prior $0.27 per share to $0.23 per share. The 2018 EPS estimate rose from $0.62 to $0.64. Shares closed at $14.13 on Friday. The 52-week range is $5.93 to $14.35, and the consensus 12-month target is $17.87.

  • [By Craig Jones]

    Jon Najarian spoke on CNBC’s “Fast Money Halftime Report” about unusually high options activity in Oasis Petroleum Inc. (NYSE: OAS).

    Traders bought around 10,000 contracts of the June 10 calls in the first half of the trading session on Thursday. The trade is unusual because the average options volume in the name is a few hundred contracts. Najarian bought the calls and is planning to hold them for two weeks.

Top 10 Undervalued Stocks To Invest In Right Now

Over the past year, the performance of T. Rowe Price Blue Chip Growth (TRBCX has underscored why it pays to sit tight when a fund with a superior long-term record hits a speed bump. In 2016, as investors turned away from shares of the fast-growing, large-capitalization stocks that Blue Chip targets in favor of more-undervalued fare, the fund lagged the stock market dramatically. Stocks that had previously buoyed the fund, such as Amazon.com and Facebook, were suddenly a drag, says manager Larry Puglia. And energy and utility stockssectors that Blue Chip tends to ignoreperformed exceptionally well.

See Also: Kip 25 Best No-Load Mutual Funds 2017

But these kinds of style shifts dont last forever. Large-cap growth stocks, led by the technology sector, are rebounding this year, and Blue Chip is benefiting. In the first three months of 2017, the fund returned 10.4%, beating Standard & Poors 500-stock index by 4.3 percentage points. Over the past 12 months, Blue Chip, a member of the Kiplinger 25, outpaced the index by nearly a full percentage point. (Prices and returns are through March 31)

Top 10 Undervalued Stocks To Invest In Right Now: L-3 Communications Holdings, Inc.(LLL)

Advisors’ Opinion:

  • [By Paul Ausick]

    Five teams are expected to compete for the contract: Boeing Co. (NYSE: BA) has joined with Saab to offer a clean-sheet design; Northrop Grumman Corp. (NYSE: NOC) has teamed up with BAE Systems and L-3 Communications Holdings Inc. (NYSE: LLL) on another clean-sheet design; Lockheed Martin Corp. (NYSE: LMT) and Korea Aerospace Industries (KAI) are going with a modified KAI T-50; Raytheon Corp. (NYSE: RTN) has joined with Italy’s Leonardo and Canada’s CAE Inc. (NYSE: CAE) on a version of Leonardo’s M-346 trainer that it calls the T-100; and privately held Sierra Nevada has partnered with Turkish Aerospace Industries (TAI) on another clean-sheet design.

  • [By Peter Graham]

    A long term performance chart shows ViaSat, Inc plus mid to large cap communications stockslikeHarris Corporation (NYSE: HRS) and L-3 Communications Holdings, Inc (NYSE: LLL)had been moving in tandem until last yearwhile small cap Gogo Inc has underperformed:

  • [By Peter Graham]

    Headquartered in New York City, large cap L3 Technologies Inc (NYSE: LLL) employs approximately 38,000 people worldwide and is a leading provider of a broad range of communication, electronic and sensor systems used on military, homeland security and commercial platforms. L3 is also a prime contractor in aerospace systems, security and detection systems, and pilot training. The Company reported 2016 sales of $10.5 billion.

Top 10 Undervalued Stocks To Invest In Right Now: Salesforce.com Inc(CRM)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Cloud-software leader Salesforce (CRM) – my Top Pick for 2017 among large cap technology stocks — remains well positioned to reap the benefits of the transition away from on-premises solutions.

  • [By WWW.THESTREET.COM]

    “There are two things that mess up your relationships, it’s anger and fear,” explains Robbins. Robbins points to Salesforce (CRM) CEO Marc Benioff as being a total giver, which has set him up for success in business.

  • [By Peter Graham]

    On the earnings call, Ellison noted that the company had surpassed Salesforce.com, inc (NYSE: CRM) in annualized recurring cloud revenue: We are now well on our way to passing them and becoming number one in the enterprise SaaS market.”

Top 10 Undervalued Stocks To Invest In Right Now: TG Therapeutics, Inc.(TGTX)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Treehouse Foods (THS) , TG Therapeutics (TGTX) , Kinder Morgan (KMI) , Magellan Midstream Partners (MMP) , Chesapeake Energy (CHK) and Arconic (ARNC) .

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Thursday's regular session.

  • [By Brian Orelli]

    TG Therapeutics (NASDAQ:TGTX)rose 15% today, after an analyst at Jefferies initiated coverage with a buy and a $23 price target.

    So what

    Analyst action often has an effect on company’s stock price, especially in the short term, but today’s move may be exacerbated by an upcoming data release at the American Academy of Neurology meeting scheduled for Friday. Investors may have been jumping in today ahead of the binary event, hoping that Friday’s data will be positive enough to send the share price even higher.

Top 10 Undervalued Stocks To Invest In Right Now: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Todd Campbell]

    Tesaro’s (NASDAQ:TSRO)ovarian cancer drug, niraparib, will begin competing for prescriptions earlier than expected. Niraparib, which will be sold under the brand name Zejula, notched FDA approval on Monday, more than three months ahead of its June 30 decision date. The early approval setsTesaro up for a fierce battle for market share withAstraZeneca (NYSE:AZN)and Clovis Oncology (NASDAQ:CLVS), both of which market drugs that work similarly to Zejula.

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

  • [By Ben Levisohn]

    Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:

  • [By George Budwell]

    Unfortunately for Clovis and its shareholders, though, Astra’s Lynparza is currently underpriority review with the FDA as a maintenance therapy in ovarian cancer, andTesaro’s (NASDAQ:TSRO)rival PARP inhibitor Zejula gained an early approval– along with afar broader label than Rubraca — just this week.

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

Top 10 Undervalued Stocks To Invest In Right Now: Intercontinental Exchange Inc.(ICE)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Altria (MO) , Intercontinental Exchange (ICE) and Micron Technology (MU) .

    Cramer was bearish on NVIDIA (NVDA) and Reynolds American (RAI) .

Top 10 Undervalued Stocks To Invest In Right Now: Exactech Inc.(EXAC)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
  • [By Lisa Levin]

    Exactech, Inc. (NASDAQ: EXAC) shares were also up, gaining 31 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.

Top 10 Undervalued Stocks To Invest In Right Now: Cemex S.A.B. de C.V.(CX)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Cemex SAB de CV (CX) is very interesting at these levels as it seems the market is pricing in a stronger dollar (thereby reducing revenue) and thus lower growth.

  • [By Paul Ausick]

    Cemex SAB de CV (NYSE: CX) dropped about 2.4% Friday to post a new 52-week low of $7.41 after closing at $7.59 on Thursday. The 52-week high is $10.37. Volume was around 8.8 million, about 15% below the daily average of around 9.3 million. The Mexico-based cement company had no specific news.

  • [By Paul Ausick]

    Cemex SAB de CV (NYSE: CX) dropped about 2.7% Thursday to post a new 52-week low of $7.57 after closing at $7.78 on Wednesday. The 52-week high is $10.37. Volume was around 6.8 million, about 15% below the daily average of around 8.3 million. The Mexico-based cement company had no specific news.

  • [By Paul Ausick]

    Cemex SAB de CV (NYSE: CX) dropped about 1.8% Wednesday to post a new 52-week low of $7.16 after closing at $7.29 on Tuesday. The 52-week high is $10.37. Volume was around 7 million, about 20% below the daily average of around 9.5. The Mexico-based cement company had no specific news.

Top 10 Undervalued Stocks To Invest In Right Now: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was indicated down 7% at $72.85 on Thursday due to results from a seizure medication study. It was downgraded to Neutral from Overweight at Piper Jaffray, and Wedbushlowered its target for the stock.

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Johanna Bennett]

    Nothing guts a drug stock like bad clinical trial data. Shares of Ultragenyx Pharmaceutical (RARE) fell as much as 10% after a seizure medication failed in a phase II study.

    Trading at a recent $72.22, the shares were down 7.7% after earlier falling as much as 10% to $70.51

    The seizure drug UX007 was tested as a treatment for glucose transporter type-1 deficiency syndromeor Glut1 DSamong a small group of patients. Data released Wednesday showed that it only cut the rate of seizures in the drug arm by 13.4% compared to the placebo arm, falling short of statistical significance.

    Investigators, though, teased out a clinically — though not statistically — significant benefit for patients experiencing what are called absence seizures. Ultragenyx now intends to focus on that in a Phase III pivotal trial.

    Leerik analyst Joseph Schwartz called the selloff a buying opportunity.

    We had been cautious on this asset (and its two programs – G1DS and long-chain fatty acid oxidation disorder/LC-FAOD; LINK) – but believe the selling pressure after mkt. presents a buying opportunity ahead of a more de-risked X-linked hypophosphatemia (XLH) Ph.3 data in 1H17.

    Cowen analyst Eric Schmidt remained convinced of RAREs long-term prospects thanks to a diversified orphan disease pipeline. And analysts at Credit Suisse see more catalysts ahead in 2017.

    We are buyers on a pullback and we like RAREs setup for the remainder of 2017…Remaining 2017 catalysts keep us buyers on a pullback: We see Q2:17 KRN23 ph3 adult XLH data, H1:17 rhGUS FDA/EMA submission, potential KRN23 CHMP decision in mid-17 (based on late-2016 EMA submission/validation), H2:17 Ace-ER ph3 GNEM data, and potential KRN23 FDA submission in late-17/early-18 as upcoming catalysts worth owning for.

Top 10 Undervalued Stocks To Invest In Right Now: Century Aluminum Company(CENX)

Advisors’ Opinion:

  • [By Craig Jones]

    JPMorgan’s analyst Michael Gambardella downgraded Century Aluminum Co (NASDAQ: CENX) from Overweight to Neutral and reduced its price target from $22 to $14.50, citing alumina cost headwinds as the main reason for the downgrade.

Top 10 Undervalued Stocks To Invest In Right Now: Lithium X Energy Corp. (LIXXF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].

  • [By Tom Bishop]

    Lithium X Energy NPV (LIXXF) owns 50% of the Sal de los Angeles lithium brine project in the prolific “Lithium Triangle” in mining friendly Salta province, Argentina.

Top 10 Casino Stocks For 2018

Last week Renewable Energy & Power, Inc. (OTC PINK : RBNW ), a diversified corporation with markets in energy-saving technologies of LED lighting, solar and wind energy, announced a large San Francisco Bay Area electronic assembly corporation has approved the installation of 1,275 LED lights for their entire main campus.

This is the third such announcement in as many months by the Las Vegas based company. It got me thinking about what the company does and how LED lighting can impact a business’ bottom line as much as it contributes to reducing emissions and the effects of global warming. But what about LED lights in RBNW’s backyard? How much of the Vegas Strip is LED? Well, it turns out, quite a bit.

Over a year ago three of Nevadas largest casino companies MGM Resorts, Wynn, and Las Vegas Sands announced plans to source renewable energy for their hotels, a move driven both by increasing demand for responsible energy use from the companies that rent their conference halls, and a surplus of cheap power from solar farms in Nevada and California. MGM Resorts had already implemented an ambitious energy conservation effort by replacing 1.3 million light bulbs in its properties with LEDs.

Top 10 Casino Stocks For 2018: CBOE Holdings Inc.(CBOE)

Advisors’ Opinion:

  • [By David Zeiler]

    Bats Global Markets was acquired on Feb. 28 by the Chicago Board Options Exchange (Nasdaq: CBOE).

    But the Bats BZX Exchange has had a bigger role than just serving as the place where the Winklevoss ETF will be listed…

  • [By David Zeiler]

    Bitcoin futures trading started at the CBOE Global Markets Inc. (Nasdaq: CBOE) on Dec. 10 and on the much larger CME Group Inc. (Nasdaq: CME) on Dec. 18. Nasdaq Inc. (Nasdaq: NDAQ) plans to begin trading Bitcoin futures in the first half of next year.

  • [By CNNMoney Staff]

    Stocks continued to rally despite the fact that options trading was temporarily halted Monday afternoon at exchanges run by CBOE Holdings (CBOE), Nasdaq OMX (NDAQ), BATS Global Markets and Miami International Holdings due to issues at the Options Price Reporting Authority (OPRA), which provides trading data and price quotes.

  • [By Wayne Duggan]

    Wall Street has been watching bitcoin this week, with the price up another 39.8 percent to above $16,000 ahead of the highly anticipated launch of bitcoin futures trading by Cboe Global Markets Inc (NASDAQ: CBOE) starting Sunday. Bitcoin has been around for years, but bitcoin futures trading will make trading a breeze for average retail investors for the first time.

Top 10 Casino Stocks For 2018: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

  • [By Todd Campbell]

    Tesaro’s (NASDAQ:TSRO)ovarian cancer drug, niraparib, will begin competing for prescriptions earlier than expected. Niraparib, which will be sold under the brand name Zejula, notched FDA approval on Monday, more than three months ahead of its June 30 decision date. The early approval setsTesaro up for a fierce battle for market share withAstraZeneca (NYSE:AZN)and Clovis Oncology (NASDAQ:CLVS), both of which market drugs that work similarly to Zejula.

  • [By Ben Levisohn]

    Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

Top 10 Casino Stocks For 2018: Valhi Inc.(VHI)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, basic materials shares slipped by 0.61 percent. Meanwhile, top losers in the sector included Valhi, Inc. (NYSE: VHI), down 13 percent, and LSB Industries, Inc. (NYSE: LXU), down 7 percent.

Top 10 Casino Stocks For 2018: ONEOK Inc.(OKE)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    Energy infrastructure companies ONEOK (NYSE:OKE) and TransCanada (NYSE:TRP) are both emerging from the energy market downturn as stronger entities. Each made smart acquisitions, with TransCanada buying U.S. gas pipeline company Columbia Pipeline Group, while ONEOK is in the process of gobbling up its MLP,ONEOK Partners (NYSE:OKS). While these deals enhanced the growth profiles of both companies, TransCanada still stands out as the better buy for long-term income investors. Here’s why.

  • [By Garrett Cook]

    Citi maintains Buy ratings on Targa Resources (NYSE: TRGP), ONEOK (NYSE: OKE) and Oneok Partners (NYSE: OKS) citing the companies stories around natural gas liquids (NGLs).

Top 10 Casino Stocks For 2018: Gerdau S.A.(GGB)

Advisors’ Opinion:

  • [By Manikandan Raman]

    On the news, Freeport-McMoRan surged 12 percent to $10.20 and Lundin Mining climbed 12 percent to $3.33. Gerdau SA (ADR) (NYSE: GGB) rose 19 percent to $1.23, Vale SA (ADR) (NYSE: VALE) advanced 18 percent to $4.85 and Banco Bradesco SA (ADR) (NYSE: BBD) gained 11 percent to $7.15.

Top 10 Casino Stocks For 2018: Firsthand Technology Value Fund, Inc.(SVVC)

Advisors’ Opinion:

  • [By Hibah Yousuf]

    Similarly, Twitter is also the biggest holding in the Firsthand Technology Value Fund (SVVC). With just over 1 million shares of the social media platform, Twitter represents nearly 11% of the total portfolio as of mid-year. Shares of Firsthand Technology Value jumped more than 6% Friday.

Top 10 Casino Stocks For 2018: URS Corporation(URS)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Fidelty’s John Mirshekaritook a look at URS(URS) today at the Value Investing Congress.His takeaway: The stock could double in two years.

    Agence France-Presse/Getty Images

    His analysis started with URS’s use of its free cash. During the past, it hasn’t been pretty. They spent 6.3 billion on eight acquisitions, they’ve bought companies at valuations higher than own stock and return-on-equity has dropped from high teens to just 6%.

    The problem hasn’t been its business: Its return on tangible capital is 17%. Instead, the problem is that its management hasn’t maximized value through capital allocation. URS has lowest valuation: 9x 2013 cash earnings in its industry.

    Part of the problem: Management incentives are based on net income. This year, however, relative total shareholder return was added., something Mirshekari calls”a step in the right direction.” In May, URS filed an amended proxy which says it will look to change incentives from net income to return on equity and earnings per share. More importantly, it said acquisitions would end.

    If all goes right, URS could double in two years,Mirshekari says, comparing it to AECOM Technology (ACM).

    Looks a lot like AECOMM, which did something similar and rallied.

  • [By Ian Wyatt, Publisher & Chief Investment Strategist, Wyatt Investment Research]

    Fund manager John Mirshekari, of the Fidelity Low-Priced Stock Fund, recommended shares of URS (URS), an engineering and construction contractor.

Top 10 Casino Stocks For 2018: LaSalle Hotel Properties(LHO)

Advisors’ Opinion:

  • [By Marshall Hargrave]

    The other key benefit for Strategic is that it enjoys industry-leading earnings before interest, taxes, depreciation and amortization (EBITDA) per available room. For 2012, Strategic generated $81 per room of EBITDA. Compare this to top comps LaSalle Hotel (NYSE: LHO) at $74 per room and Pebblebrook Hotel Trust (NYSE: PEB) at $71. The reason for this is that Strategic is much less reliant than its peers on rooms, with much greater exposure to food and beverages. Strategic earns 53% of its revenue from rooms, while its peers get around 66% of revenues from rooms.

Top 10 Casino Stocks For 2018: Reinsurance Group of America, Incorporated(RGA)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Morgan Stanley downgraded Chipotle (NYSE: CMG) to Equal-Weight.
    UBS downgraded AMC Networks (NASDAQ: AMCX) to Sell.
    Citi upgraded Sealed Air (NYSE: SEE) to Buy.
    Goldman Sachs upgraded Reinsurance Group (NYSE: RGA) to Buy.

  • [By David Sterman]

    My favorite insurers: AIG (NYSE: AIG) (which I discussed a few months ago), Protective Life (NYSE: PL) and Reinsurance Group of America (NYSE: RGA).

Top 10 Casino Stocks For 2018: Portola Pharmaceuticals, Inc.(PTLA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares dropped 30 percent to $20.08 after announcing Phase III Betrixaban results.

    Shares of Spark Energy Inc (NASDAQ: SPKE) were down 14 percent to $20.96. Spark Energy reported Q4 GAAP EPS of $(0.01) and adjusted EBITDA of $16.3 million.

  • [By Lisa Levin]

    Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares dropped 23 percent to $21.92 after announcing Phase III Betrixaban results.

    Shares of Spark Energy Inc (NASDAQ: SPKE) were down 16 percent to $20.43. Spark Energy reported Q4 GAAP EPS of $(0.01) and adjusted EBITDA of $16.3 million.

  • [By Lisa Levin]

    Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares were also up, gaining 46 percent to $55.68 after the company disclosed that the FDA has approved Bevyxxa, a blood-thinner for acutely ill patients not undergoing surgery. BevyxXa is the first oral drug of its kind to be approved to help prevent deep vein thrombosis and pulmonary embolisms..

  • [By Todd Campbell]

    Portola Pharmaceuticals’ (NASDAQ:PTLA)could have two commercial-stage drugs on the market next year, but turning them into top-sellers will require a lot of money. Is Portola Pharmaceuticals’ balance sheet flush enough with cash to get its drugs across the finish line?

Top 10 Medical Stocks To Watch Right Now

Image source: Getty Images.

What happened

Shares of Insulet Corporation(NASDAQ:PODD), a medical device company primarily focused on diabetes,rose by as much as 11% in afternoon trading on Friday.

So what

The drug delivery specialist didn’t release any news on Friday that could justify its big move.Instead, Insulet’s stock appears to be rising in response to goodnews that was released by one of the company’s partners.

DexCom (NASDAQ:DXCM), a diabetes-focused company that makes continuous glucose monitors, announced on Thursday evening that theCenters for Medicare & Medicaid Services (CMS) has officially decided to cover its G5 Mobilesystem.

DexCom’s CEO Kevin Sayer was thrilled with the news, stating, “This landmark CMS Ruling will make available the most important technology in diabetes management to theMedicarepopulation.”

Top 10 Medical Stocks To Watch Right Now: Glu Mobile Inc.(GLUU)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows that Zynga Inc peaked after the IPO, but has at least been less volatile since then compared to the performance of remaining small cap mobile gaming stockGlu Mobile Inc (NASDAQ: GLUU) and large capActivision Blizzard:

  • [By Peter Graham]

    Small cap mobile game stock Glu Mobile Inc (NASDAQ: GLUU) reportedQ2 2017 earnings after the market closed on Tuesday. Revenue grew 42% year over year to $68.7 million while bookingsincreased 62% to$82.5 million (whichexceed high end of guidance) and Design Home peaked as the#17 top grossing game on U.S. App Store for iPhone. The net loss was $23.568 million versus a net loss of $17.949 million. The Company also raised 2017 full year bookings guidance to a range of $307 million to $312 million.

  • [By Peter Graham]

    A long term performance chart shows that Zynga Inc largely moving sideways for the pastthree years or sowhile remaining small cap mobile gaming stockGlu Mobile Inc (NASDAQ: GLUU) has underperformed andlarge capActivision Blizzard continues to have a good run:

  • [By Lee Jackson]

    Glu Mobile Inc. (NASDAQ: GLUU) was started with a Neutral rating and a $2.30 price objective at Mizuho. The Wall Street estimate is$2.56. The 52-week range is $1.73 to $4.00, and the stock closed yesterday at $2.10.

Top 10 Medical Stocks To Watch Right Now: Mitsubishi Corporation (MSBHY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Renault Nissan (OTC:RNSDF) (NSANY)/Mitsubishi (OTCPK:MSBHY) (MMTOF)

    On December 20, Green Car Reports reported: “Mitsubishi electric cars to use Nissan-Renault platforms.” Remember Mitsubishi has the US$22,995 all-electric 16 kWh iMiEV coming out in 2017.

  • [By SEEKINGALPHA.COM]

    Mitsubishi (OTCPK:MSBHY)

    Earlier in 2016, Mitsubishi released its 2017 i-MiEV. It is fully electric, with a 16 kWh lithium-ion battery pack and a range of 62 miles. Basically just a short trips car, as the range is really very low. Mitsubishi also has its popular plug in hybrid Outlander model that sells quite well. As stated last month, the company announced “plans to launch a compact EV with 250-mile range by 2020”. Mitsubishi is currently ranked 7th in global EV sales.

Top 10 Medical Stocks To Watch Right Now: Aphria Inc. (APHQF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Some of you may have seen the joint press release this morning from Aphria Inc. (OTCQB:APHQF) and Liberty Health Sciences Inc. (OTCPK:SCQBD) regarding their response to TMX Group’s “regulatory engagement.” Some people contacted us asking questions like how are the two companies related?, and more. Don’t worry – we’ve got you covered!

  • [By Keith Speights]

    There are plenty of reasons for investors to like three marijuana stocks in particular — GW Pharmaceuticals (NASDAQ:GWPH), Insys Therapeutics (NASDAQ:INSY), and Aphria (NASDAQOTH:APHQF). In fact, there are at least 661 million reasons. That’s the amount of cash in U.S. dollars that the three companies have combined. Here’s why the cash stockpiles held by GW, Insys, and Apria are important.

  • [By Keith Speights]

    As increasingly more marijuana growers entered the market and more states allowed residents to legally grow marijuana, cannabis prices dropped throughout 2016. Wholesale marijuana prices late in the year were roughly half the levels of 12 months earlier. Will this trend continue — and possibly hurt leading marijuana stocks including Aphria (NASDAQOTH:APHQF),Aurora Cannabis (NASDAQOTH:ACBFF), Medical Marijuana,Inc.(NASDAQOTH:MJNA), and even GW Pharmaceuticals (NASDAQ:GWPH) in the process?

Top 10 Medical Stocks To Watch Right Now: Envision Healthcare Holdings, Inc.(EVHC)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Even on a day like today, somebody had to be the worst performer in the S&P 500, and today that somebody is Envision Healthcare (EVHC), which missed earnings forecasts last night.

  • [By Paul Ausick]

    Envision Healthcare Corp. (NYSE: EVHC) dropped about 9.3% Tuesday to post a new 52-week low of $43.22 after closing Monday at $47.67. The 52-week high is $74.75. Volume of around 10 million shares traded was about six times the daily average. The company had no specific news.

  • [By Lisa Levin]

    Envision Healthcare Holdings Inc (NYSE: EVHC) shares shot up 211 percent to $70.15. Envision Healthcare and Amsurg Corp (NASDAQ: AMSG) reported the completion of their merger.

Top 10 Medical Stocks To Watch Right Now: Veeco Instruments Inc.(VECO)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    VECO (NASDAQ:VECO) contributed 1.16% to the Fund’s quarterly return, nearly equaling AAN’s contribution in the quarter. VECO appreciated over 48% in the quarter due to an acceleration of orders for its key MOCVD tools. These tools are the main manufacturing equipment used to produce LEDs, whether they are for display screens or, increasingly, for lighting products. We estimate that VECO currently has roughly 80% global market share for MOCVD tools used to make LEDs.

Top 10 Medical Stocks To Watch Right Now: General Motors Company(GM)

Advisors’ Opinion:

  • [By Paul Ausick]

    Among the Detroit Three the outlook is decidedly mixed. According to researchers at Kelley Blue Book (KBB), General Motors Co. (NYSE: GM) is forecast to sell 249,000 units, up 8.6% compared with November of 2015. GM’s U.S. market share is expected to reach 18.2%, up 0.7 percentage point year over year. Ford Motor Co. (NYSE: F) is touted to post a sales gain of just 0.1% with 189,000 units for a market share of 13.6%, down 0.6 point year over year. Fiat Chrysler Automobiles NV (NYSE: FCAU) is forecast to see unit sales drop 4.5% year over year to 168,000 and a market share of 12.3%, down 1.1 percentage points.

  • [By WWW.THESTREET.COM]

    IBM was among a number of companies Trump hit on the campaign trail for shipping jobs overseas. He accused the company of laying off 500 workers in Minneapolis and moving their jobs to India at a Minnesota rally just a day before the election. He made similar attacks against Ford (F) , Apple (AAPL) and General Motors (GM) , among others.

  • [By Lisa Levin]

    General Motors Company (NYSE: GM) reported better-than-expected results for its fourth quarter.

    GM reported Q4 adjusted earnings of $1.28 per share on revenue of $43.9 billion, Analysts were expecting earnings of $1.17 per share on revenue of $41.5 billion.

  • [By Michael A. Robinson]

    If you still find the idea of self-driving cars hard to believe, consider this…

    Uberbegan testing driverless cars inPittsburghearlier this year, and the Obama administration has endorsed the push to develop these vehicles.Alphabet Inc.(Nasdaq:GOOGL)has fielded a fleet of autonomous cars, under its Chauffeur division, that have logged a combined 2 million miles in the last four years. (Although the execs there are in the process of refocusing that division – with an announcement coming as soon as today.)Ford Motor Co. (NYSE:F)andBMW AGare working to produce driverless cars by 2021.General Motors Co. (NYSE:GM)has invested $500 million in ride-sharing startup Lyft, and the two are working on autonomous vehicles together.And in April 2015, anAudi SQ5drove 3,400 miles across the country almost entirely “hands free.”

    On that journey from San Francisco to New York, the car had to guide itself through big-city rush hours, road construction, confusing street signs, and diverse weather.

Top 10 Medical Stocks To Watch Right Now: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Who has PARP? A poly ADP-ribose polymerase inhibitor (PARPi) kills cancer cells by interfering tumor DNA repair pathway with the potential to treat ovarian, breast and prostate cancer. Studies have shown that patients with BRCA mutations (BRCAmut) respond to PARPi. AstraZenecas (AZN) PARPi was approved in 2014 whileClovis Oncology (CLVS) and Tesaro (TSRO) both have positive Phase III data. Clovis licensed its PARPi from Pfizer (PFE) in 2011 and Tesaro licensed its PARPi from Merck (MRK) in 2012, after Sanofis (SNY) PARPi (later demonstrated that it cannot block PARP) failed in Phase III in early 2011.

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

  • [By Ben Levisohn]

    Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:

  • [By Todd Campbell]

    Tesaro’s (NASDAQ:TSRO)ovarian cancer drug, niraparib, will begin competing for prescriptions earlier than expected. Niraparib, which will be sold under the brand name Zejula, notched FDA approval on Monday, more than three months ahead of its June 30 decision date. The early approval setsTesaro up for a fierce battle for market share withAstraZeneca (NYSE:AZN)and Clovis Oncology (NASDAQ:CLVS), both of which market drugs that work similarly to Zejula.

Top 10 Medical Stocks To Watch Right Now: 3M Company(MMM)

Advisors’ Opinion:

  • [By Chris Lange]

    3M Company (NYSE: MMM) is set to report its second-quarter results on Tuesday. The analysts consensus estimates call for EPS of $2.54 and $7.86 billion in revenue. Shares of 3M were changing hands at $211.07 at Fridays close. The consensus price target is $205.09, and the 52-week range is $163.85 to $214.57.

  • [By Paul Ausick]

    3M Company (NYSE: MMM) traded down 1.05% at $210.38. The stock’s 52-week range is $163.85 to $214.57. Volume was about 20% below the daily average of around 1.8 million. The company had no specific news.

  • [By Paul Ausick]

    3M Company (NYSE: MMM) traded up 0.91% at $201.53. The stock’s 52-week range is $163.85 to $214.57. Volume was about half the daily average of around 1.8 million shares. The company had no specific news Monday.

Top 10 Medical Stocks To Watch Right Now: Kate Spade & Company(KATE)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Kate Spade (KATE) caught a bounce on Wednesday when the Wall Street Journalreported that it was actively seeking a buyer. Since then, we’ve learned that the fashion accessories retailer looks set to auction itself off to the highest bidder, with the process potentially beginning next month, with bidders potentially including Coach (COH) and Michael Kors (KORS). In a note today, SunTrust Robinson Humphrey analystPamela Quintiliano and team contend that Kate Spade could fetch as much as $23 a share:

    Getty Images

    Looking at recent historical deals, we arrive at a $18-$23 potential deal range. We analyzed transactions that have been announced over the past four years and involved companies catering to a higher income customer. These deals include Southern Tide (acquired by Oxford Industries (OXM)), Joe’s Jeans (acquired by Sequential Brands Group (SQBG)), prAna (acquired by Columbia Sportswear (COLM)), The Jones Group (acquired by Sycamore Partners [private] and Juicy Couture (acquired by Authentic Brands Group [private]). The average EV/EBITDA multiple of these transactions are 12.9x (in line with KATE’s 5-year historical average of 12.1x) and implies a potential deal range of $22-$23. When taking the average of recent (F13-16) deals implies an ~10.5x EV/EBITDA multiple. When applying the ~10.5x multiples to KATE’s trailing EBITDA, we arrive at an $18- $19 potential share price.

    Shares of Kate Spade have gained 1.1% to $18.70 at 2:08 p.m. today, while Coach has declined 0.2% to $34.95, Michael Kors is little changed at $42.86, Oxford Industries has fallen 0.7% to $60.38, Columbia Sportswear has climbed 1.4% to $58.60, and Sequential Brands Group has jumped 3.7% to $4.77.

  • [By Ben Levisohn]

    Coach (COH) rose to the top of the S&P 500 today after reports that Kate Spade (KATE) had put itself up for sale caused shares of fashion-accessory retailers to rise.

  • [By Ben Levisohn]

    Time, time, time. See what’s become of Kate Spade (KATE), as investors look around at its possibilities…and don’t like what they see. That’s the takeaway today following Kate Spade’s earnings release, and update on a potential takeover.

    Getty Images

    Kate Spade reported a profit of 1 cent a share, missing forecasts for 7 cents, on sales of $271.2 million, well below analyst expectations for $299 million. And Kate Spade also updated investors on its efforts to sell itself, without offering much of an update at all.

    Cowen’s Oliver Chen and team still expect a deal to happen but lower the probability of a deal occurring to 70% from 80%. They explain why:

    …formal language on deal prospects articulates process is proceeding in a timely manner with no definitive timetable and no assurance that process will result in a transaction. We still expect a deal to happen, but do lower our probability from 80% to 70% given the likelihood that potential buyer(s) and KATE have not agreed on a clearing price in earlier rounds of negotiation. We believe a bidder such as Coach (COH) does not want to overpay, is disciplined about managing ROIC, and returns and synergies split may be more rational at an offer price in the range of $22-25. We continue to believe KATE has a long global growth runway ahead with opportunities for store growth abroad, further expansion into non-handbag categories, and supply + digital synergy potential…We rate KATE Market Perform and lower our price target to $21 (was $27). Our updated valuation is based on ~10x our FY18E adj. EBITDA or $284mm.

    Investors, however, want to see a deal get done: Shares of Kate Spade have tumbled 6.6% to $18.12 at 3:26 p.m. today, while Coach has declined 0.5% to $39.51, and Michael Kors (KORS), also rumored to be interested in an acquisition, has fallen 1.1% to $36.92.

  • [By Ben Levisohn]

    Ever since peaking in late April, Kate Spade’s (KATE) shares have been in a downward spiral so pronounced that even an amateur technical analyst like myself could draw its trend line lower. Today, however, its shares are soaring after the Wall Street Journal reported that Kate Spade was actively seeking a buyer.

    Getty Images

    Mizuho’s Betty Chen and Alex Pham run the math on a possible acquisition price:

    When we examined historical transactions in the specialty retail sector, we noticed a wide range of valuations. Select relevant transactions to consider would be ~2x EV/Sales Coach (COH) paid for Stuart Weitzman, Samsonites acquisition of Tumi at 14x EV/EBITDA, 13x EV/EBITDA for Joseph A. Banks by Mens Wearhouse (TLRD) and Kerings acquisition of Volcom for 18x EV/EBITDA. We believe potential valuation could be as high as ~2x EV/ Sales and ~14x EV/EBITDA given Kate Spade’s unique growth profile to expand to ~$4bn in revenue (from $1.4bn in FY16) and improving profitability from 12% EBIT margin TY to at least HTeens-LDD, in our view (Coach is 18.7% and Michael Kors (KORS) is 21.3%). On these two metrics, Kate Spade would be valued at $21-23…

    We believe the growth profile coupled with the brands unique appeal to Millennials and broad-based success across categories ranging from handbags to apparel and jewelry could be attractive to many buyers, including Coach, which was rumored to be evaluating the company in recent weeks.

    The news has sent shares of Kate Spade soaring: They’re up 24% at $18.03 at 2:11 p.m., a gain that has turned this year’s 18% loss as of last night into a 2% gain during afternoon trading.

    The move has also put a dent in Kate Spade’s downtrend (and now you’ll see my amateur technical analysis abilities at work):

    FactSet

    That’s one way to break a downtrend.

  • [By Lisa Levin]

    Kate Spade & Co (NASDAQ: KATE) was down, falling around 14 percent to $19.60 after it was reported the company would spend more time to negotiate the Coach Inc (NYSE: COH) offer.

Top 10 Medical Stocks To Watch Right Now: Internationa Flavors & Fragrances, Inc.(IFF)

Advisors’ Opinion:

  • [By Lee Jackson]

    International Flavors & Fragrances Inc. (NYSE: IFF) is yet another company that hit our screens witha 10% institutional owner buying stock twice last week. Winder Investment purchased a total of 70,000 shares. At $128.38per share, the total for the trade was a solid $9 million. Later in the week the company stepped in again and bought another100,000 shares at prices between $129.47 and 132.20 apiece. The total for that buy was posted at $13 million. The shares closed trading last Friday at $133.19, so some timely buys for sure. The 52-week trading range is $112.91 to $143.64. The consensus price target is $131.40.